J Breast Cancer.  2009 Mar;12(1):14-19. 10.4048/jbc.2009.12.1.14.

Expression Profiles of Retinoblastoma Protein and p27Kip1 According to HER2 Amplification Status in Primary Breast Cancer

• Shin JH
• Park SJ
• Cho HJ
• Gwak G
• Bae BN
• Kim KW
• Kim HY
• Park K
• Han S

• KMID: 2286573
• DOI: http://doi.org/10.4048/jbc.2009.12.1.14

Abstract

PURPOSE: Human epidermal growth factor receptor-2 (HER-2)/neu amplification affects the cell proliferation through the modulation of multiple G1 cell cycle regulators in breast tumor cells. We performed this study to investigate whether retinoblastoma protein (pRB) and p27Kip1 were differently expressed according to the HER2 amplification status in human breast cancer.
METHODS
HER2 amplification was assayed by fluorescence in situ hybridization and the expression of cell cycle regulators were assayed by immunohistochemistry on 153 consecutive invasive breast cancers. The proliferative activity of breast cancer was analyzed according to the HER2 amplification and cell cycle protein expression status.
RESULTS
HER2 amplification was observed in 39 (25.5%) of 153 breast cancers. In the HER2 amplified breast cancers, the pRB expression was significantly increased (p=0.011) whereas there was no significant relationship between HER2 amplification and p27Kip1 expression. There was an inverse correlation between pRB expression and Ki-67 labeling index in the HER2 amplified breast cancers (p=0.036). In contrast, Ki67 labeling index was significantly decreased as p27Kip1 expression increased in HER2 non-amplified breast cancers (p=0.028). In HER2 non-amplified breast cancers, we could not observe any association between the pRB expression and Ki67 labeling index.
CONCLUSION
The proliferation of the breast cancers was associated with pRB expression in HER2 amplified tumors whereas it was associated with p27Kip1 expression in HER2 non-amplified tumors. The results of the current study indicate that the cell proliferative activity of the breast cancer is under different growth signal pathways according to HER2 amplification status.

Keyword

Breast cancer; Cell proliferation; HER2; pRB; p27Kip1

MeSH Terms

Breast
Breast Neoplasms
Cell Cycle
Cell Proliferation
Epidermal Growth Factor
Fluorescence
Humans
Immunohistochemistry
In Situ Hybridization
Retinoblastoma
Retinoblastoma Protein
Signal Transduction
Epidermal Growth Factor
Retinoblastoma Protein

Reference

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WJ. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987. 235:177–182.

2. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998. 20:41–48.

3. Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W, et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene. 2000. 19:1647–1656.

4. Lenferink AE, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways. Cancer Res. 2001. 61:6583–6591.

5. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994. 78:59–66.

6. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin/cdk protein kinase activity, is related to p21. Cell. 1994. 78:67–74.

7. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21Cip1. EMBO J. 1999. 18:5310–5320.

8. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999. 18:5321–5333.

9. Bok SH, Gwag G, Yang KH, Bae BN, Kim KH, Kim HJ, et al. Proliferative markers of breast cancer. J Breast Cancer. 2005. 8:165–171.

10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991. 19:403–410.

11. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2001. 2:127–137.

12. Elledge SJ. Cell cycle checkpoints: preventing an identity crisis. Science. 1996. 274:1664–1672.

13. Hunter T, Pines J. Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell. 1994. 79:547–550.

14. Sgambato A, Flamini G, Cittadini A, Weinstein IB. Abnormalities in cell cycle control in cancer and their clinical implications. Tumori. 1998. 84:421–433.